Pharmacology

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

May 04, 2026 Reported by AI

A major Cochrane review of 17 clinical trials involving over 20,000 participants has concluded that drugs targeting amyloid beta in the brain provide no meaningful benefits for patients with mild cognitive impairment or early Alzheimer’s. These treatments also raise the risk of brain swelling and bleeding. Researchers urge a shift to alternative pathways for future treatments.

Researchers have discovered why polyamines, compounds promoted for anti-aging benefits, may also promote cancer growth. The study shows that these molecules activate different proteins in healthy versus cancerous cells, leading to contrasting effects. Led by experts at Tokyo University of Science, the findings were published in the Journal of Biological Chemistry.

March 01, 2026 Reported by AI Fact checked

Researchers at Adelaide University report that salcaprozate sodium (SNAC)—an absorption enhancer used in oral semaglutide tablets—was associated with changes in gut bacteria and inflammation markers in an animal study conducted over 21 days. The authors said the findings do not demonstrate harm in humans but argue that longer-term research is needed as oral options for obesity treatment expand.

After 11 years of research, scientists at McMaster University have identified a molecule called butyrolactol A that weakens deadly fungi, making them vulnerable to existing treatments. This discovery targets pathogens like Cryptococcus neoformans, which pose severe risks to immunocompromised individuals. The finding could revive outdated antifungal drugs amid rising resistance.

January 20, 2026 Reported by AI

New research indicates that regular use of ibuprofen, a common painkiller, may reduce the risk of endometrial cancer by up to 25% in certain women. This finding comes from a large-scale study analyzing over 42,000 participants, highlighting the drug's anti-inflammatory properties. However, experts caution against using it for prevention due to potential side effects.